EVT801 is an orally available, selective VEGFR-3 inhibitor (IC50 = 11 nM) with antitumor activity; it inhibits VEGF-C-induced proliferation of human endothelial cells and suppresses tumor (lymph)angiogenesis in mouse tumor models; it reduces tumor hypoxia, decreases production of immunosuppressive cytokines (CCL4, CCL5) and myeloid-derived suppressor cells (MDSCs); and it synergizes with immune checkpoint therapy (ICT) to enhance ICT response rates and improve antitumor efficacy in cancer mouse models.